sever
acut
respiratori
syndrom
sar
first
report
guangdong
provinc
china
novemb
sinc
spread
asian
countri
north
america
europ
outbreak
reportedli
affect
individu
juli
result
death
sar
character
high
fever
malais
rigor
headach
nonproduct
cough
dyspnea
may
progress
gener
interstiti
infiltr
lung
requir
intub
mechan
ventil
unpreced
respons
world
health
organ
call
upon
lead
laboratori
world
set
multicent
research
investig
etiolog
sar
develop
effect
diagnost
test
aid
modern
inform
technolog
set
secur
websit
share
emerg
scientif
inform
among
sever
laboratori
critic
result
includ
electron
micrograph
virus
sequenc
genet
materi
identif
character
viru
viru
isol
sampl
patient
postmortem
tissu
share
real
time
goal
pin
caus
agent
sar
develop
diagnost
tool
within
month
novel
coronaviru
isol
patient
sar
within
day
comparison
sequenc
coronaviru
polymeras
gene
previous
character
strain
scientist
conclud
viru
distinct
previous
known
human
pathogen
month
outbreak
new
ill
announc
new
pathogen
member
coronaviru
famili
never
seen
human
caus
sar
remark
scientif
collabor
assembl
among
team
scientist
laboratori
countri
novel
coronaviru
identifi
etiolog
agent
sar
public
health
measur
includ
rapid
identif
sar
case
isol
contact
ultim
succeed
control
sar
epidem
howev
identif
anim
reservoir
viru
possibl
reemerg
epidem
pandem
sar
provid
strong
motiv
develop
antivir
agent
treat
potenti
fatal
respiratori
ill
coronavirus
famili
posit
strand
envelop
rna
virus
caus
respiratori
gastrointestin
neurolog
diseas
coronaviru
virion
compos
helic
nucleocapsid
surround
lipid
bilay
envelop
stud
virusspecif
glycoprotein
helic
nucleocapsid
structur
contain
singlestrand
posit
sens
rna
genom
surround
nucleocapsid
protein
n
viral
envelop
contain
membran
glycoprotein
envelop
protein
e
spike
glycoprotein
sarscov
replicas
encod
kb
kb
viral
genom
rna
genom
rna
translat
produc
two
replicas
polyprotein
term
kilodalton
kda
polyprotein
predict
contain
singl
papainlik
proteas
plpro
analog
second
murin
coronaviru
plpro
domain
picornaviru
proteas
domain
also
sometim
note
mpro
main
proteas
three
put
membran
protein
sever
addit
product
unknown
function
kda
gener
ribosom
frameshift
extend
product
includ
open
read
frame
contain
core
rna
polymeras
helic
domain
addit
product
unknown
function
polyprotein
predict
process
gener
protein
product
term
nonstructur
protein
assembl
form
membraneassoci
viral
replic
complex
proteolyt
process
coronaviru
replicas
polyprotein
essenti
ongo
viral
rna
synthesi
therefor
sarscov
proteas
attract
target
develop
antivir
drug
reduc
viral
replic
pathogen
structur
activ
coronaviru
alreadi
elucid
design
inhibitor
therapeut
propos
sarscov
three
domain
residu
ii
residu
iii
residu
domain
ii
contain
activ
site
region
bbarrel
domain
iii
ahel
domain
activ
site
cystein
residu
act
nucleophil
histidin
residu
act
gener
acid
base
xray
crystal
structur
relat
enzym
porcin
transmiss
gastroenter
coronaviru
tgev
substrateanalogu
hexapeptidyl
chloromethyl
keton
cmk
inhibitor
cbzvalasnserthrleuglncmk
report
sequenc
inhibitor
design
base
upon
residu
ntermin
autoprocess
site
tgev
correspond
sequenc
sarscov
thrseralavalleu
tyrglythrleugln
respect
bind
mode
hexapeptidyl
gln
inhibitor
similar
observ
relat
human
rhinoviru
proteas
prototyp
inhibitor
human
rhinoviru
appear
bind
enzym
orient
similar
peptidyl
cmk
inhibitor
bind
site
tgev
furthermor
substrat
specif
picornaviru
similar
coronaviru
consequ
compound
becom
start
point
design
sarscov
inhibitor
design
synthesi
two
analogu
recent
report
base
upon
report
sarscov
structur
modifi
chang
side
chain
pfluorobenzyl
group
smaller
benzyl
prenyl
group
inhibitor
possess
bunsatur
ester
function
coval
link
compound
inact
sarscov
cellcultur
assay
antivir
activ
report
mgml
modifi
analogu
potent
sarscov
k
inact
valu
effect
sarscov
cell
assay
ic
valu
well
toxic
observ
mm
moreov
xray
crystal
structur
sarscov
coval
link
synthet
small
molecul
inhibitor
report
addit
import
coval
bond
form
proteas
xray
structur
also
show
crucial
hydrogen
bond
reveal
import
insight
molecular
recognit
type
inhibitor
sarscov
xray
crystal
structur
substratelik
azapeptid
epoxid
inhibit
sarscov
publish
inhibitor
specif
clan
cd
cystein
peptidas
also
lead
candid
sarscov
catalyt
dyad
activ
site
best
inhibit
obtain
diastereom
compound
k
inact
k
ms
crystal
structur
reveal
coval
bond
form
catalyt
sulfur
atom
epoxid
model
studi
four
diastereom
bind
sarscov
nucleophil
attack
explain
necess
configur
epoxid
anoth
import
seri
coval
inhibitor
recent
disclos
seri
tripeptid
bunsatur
ester
ketomethylen
isoster
assay
target
sarscov
ketomethylen
isoster
tripeptid
bunsatur
ester
contain
phenylalanin
residu
show
modest
inhibitori
activ
ic
mm
pheph
dipeptid
inhibitor
design
basi
comput
model
enzymeinhibitor
complex
potent
inhibitor
compound
inhibit
constant
mm
cellbas
assay
also
indic
nontox
antisar
agent
ec
valu
mm
ic
valu
mm
comput
studi
structureact
relationship
show
hydrogen
bond
main
chain
side
chain
crucial
inhibitori
potenc
side
effect
toxic
often
aris
coval
bond
inhibitor
hinder
prevent
develop
use
drug
therapi
avoid
pitfal
often
desir
design
develop
noncoval
revers
inhibitor
therapeut
agent
seri
synthet
small
molecul
noncoval
inhibitor
sarscov
publish
investig
previous
report
ketoglutamin
analogu
phthalhydrazido
group
aposit
revers
inhibitor
hepat
viru
hav
proteinas
ic
valu
inhibitor
low
micromolar
rang
synthes
seri
ketoglutamin
analogu
phthalhydrazido
group
aposit
attach
tripeptid
acvalthrleu
inhibitor
sarscov
combin
effect
b
b
amino
group
adjac
keto
group
intramolecular
hydrogen
bond
carbonyl
make
electrophil
result
carbonyl
group
form
hemithioacet
sulfur
k
valu
revers
inhibitor
remain
determin
diversifi
librari
peptid
anilid
prepar
inhibitori
activ
examin
sarscov
fluorogen
tetradecapeptid
substrat
potent
compound
k
valu
mm
analogu
examin
show
substanti
reduc
inhibitori
activ
associ
dock
studi
show
dimethylamino
chloro
nitro
group
occupi
r
r
r
posit
respect
make
import
interact
sever
residu
sarscov
interact
calcul
respons
kcalmol
energi
differ
compound
analogu
use
assay
methodolog
ic
valu
trypsin
chymotrypsin
papain
determin
mm
respect
compound
one
potent
inhibitor
sarscov
report
date
importantli
competit
inhibitor
form
coval
bond
proteas
seri
synthet
isatin
deriv
also
report
noncoval
sarscov
inhibitor
known
certain
isatin
compound
potent
inhibitor
rhinoviru
sarscov
rhinoviru
similar
activ
site
catalyt
residu
isatin
deriv
may
good
candid
sarscov
inhibitor
sarscov
inhibit
assay
conduct
via
fluoresc
reson
energi
transfer
fret
accord
report
protocol
isatin
deriv
inhibit
sarscov
low
micromolar
rang
mm
among
compound
potent
inhibitor
comput
model
show
compound
fit
activ
pocket
sarscov
two
carbonyl
group
isatin
form
hydrogen
bond
nh
group
side
chain
analysi
activ
site
sarscov
reveal
presenc
cluster
serin
residu
seri
aryl
boron
acid
deriv
show
high
bind
affin
shown
inhibit
constant
low
micromolar
rang
compound
amid
group
linkag
potent
extens
screen
carri
effort
find
structur
lead
sarscov
exist
drug
major
advantag
approv
drug
minim
modif
may
possibl
gain
acceler
approv
us
food
drug
administr
report
kaletra
mixtur
proteas
inhibitor
lopinavir
ritonavir
approv
treat
hiv
show
effect
sar
viru
base
observ
bind
affin
six
drug
investig
sarscov
includ
lopinavir
ritonavir
niclosamid
promazin
two
hiv
inhibitor
pnu
preliminari
result
indic
drug
could
use
templat
design
sarsproteas
inhibitor
collect
nearli
synthet
compound
natur
product
screen
assay
use
sarscov
vero
cell
sarscov
inhibiton
assay
antihiv
agent
compound
found
inhibit
sarscov
k
valu
mm
show
protect
effect
viral
replic
assay
concentr
mm
dock
simul
show
fold
ringlik
structur
activ
site
along
similar
line
compound
librari
consist
commerci
avail
drug
biolog
activ
substanc
screen
inhibit
sarscov
potent
inhibit
achiev
mercurycontain
compound
thimeros
phenylmercur
acet
hexachlorophen
mm
rang
compound
inhibit
viral
replic
vero
cell
cultur
detail
mechanist
studi
use
fluorescencebas
proteas
assay
demonstr
three
compound
act
competit
inhibitor
k
mm
phenylmercur
acet
thimeros
hexachlorophen
respect
howev
mercurycontain
compound
pose
toxic
problem
panel
metal
ion
includ
zn
conjug
also
evalu
antisarscov
activ
among
zinc
shown
potent
competit
inhibitor
k
mm
addit
zinccontain
compound
eg
zinc
acet
supplement
drug
wilson
diseas
suggest
zinc
ion
may
safe
human
use
base
concept
chemic
genet
structur
divers
small
molecul
screen
yield
compound
antisarscov
activ
compound
target
sarscov
show
potent
inhibitori
activ
ic
mm
ec
mm
vero
cellbas
sarscov
plaqu
reduct
assay
anoth
group
research
use
quench
fret
assay
fulli
autom
system
screen
druglik
molecul
result
hit
appli
seri
virtual
experiment
filter
five
structur
novel
molecul
identifi
show
potent
inhibitori
activ
ic
mm
sarscov
inhibitori
activ
five
compound
four
differ
proteas
hav
chymotrypsin
papain
also
examin
result
two
compound
show
appar
select
sarscov
screen
databas
contain
structur
inform
exist
drug
identifi
serotonin
antagonist
cinanserin
sq
homolog
model
crystallograph
structur
bind
pocket
sarscov
util
dock
studi
follow
experi
show
cinanserin
hydrochlorid
bind
sarscov
ic
mm
respect
forti
compound
emerg
virtual
dock
screen
postdock
screen
filter
includ
pharmacophor
model
consensu
score
druglik
filter
appli
among
three
compound
found
inhibit
sarscov
calmodulin
antagonist
calmidazolium
show
k
valu
mm
moreov
calmidazolium
noncoval
inhibitor
ethacryn
acid
deriv
also
test
nonpeptid
coval
inhibitor
sarscov
ethacryn
acid
amid
show
k
valu
mm
fluorimetr
assay
use
novel
fret
pairlabel
substrat
final
three
natur
product
contain
tea
tanic
acid
digal
also
show
inhibitori
properti
sarscov
ic
valu
mm
numer
studi
structur
mechanist
aspect
sarscov
provid
multipl
avenu
structurebas
design
antivir
compound
target
activ
site
hand
structurebas
design
membraneassoci
plpro
enzym
either
sarscov
relat
coronavirus
remain
elus
due
lack
structur
inform
unlik
mani
coronavirus
encod
two
plpro
paralog
sarscov
singl
copi
plpro
cleav
three
site
n
terminu
releas
respect
interestingli
cleavag
site
bear
strong
resembl
ctermin
tail
ubiquitin
consensu
sequenc
lxgg
result
hypothes
sarscov
plpro
may
deubiquitin
activ
recent
catalyt
domain
plpro
purifi
shown
effici
disassembl
diand
branch
polyubiquitin
chain
cleav
substrat
deisgyl
activ
report
sarscov
plpro
inhibit
specif
deubiquitin
enzym
inhibitor
ubiquitin
aldehyd
inhibit
constant
mm
howev
role
deubiquitin
deisgyl
activ
viru
replic
cycl
remain
unclear
sarscov
plpro
consid
equal
viabl
target
drug
design
essenti
viral
replic
howev
plpro
like
pursu
pauciti
structur
inform
recent
catalyt
core
sarscov
plpro
crystal
xray
structur
determin
structur
sarscov
plpro
first
elucid
coronaviru
plpro
inform
provid
signific
insight
deubiquitin
function
vitro
expand
avail
structur
templat
sarscov
enzym
target
discoveri
novel
therapeut
compound
halt
replic
sarscov
sinc
viral
entri
cell
first
step
viral
infect
attract
target
antisar
chemotherapi
block
entri
viru
may
effect
minim
chanc
viru
evolv
acquir
drug
resist
domain
sarscov
spike
glycoprotein
effici
bind
metallopeptidas
angiotensinconvert
enzym
viru
entri
step
also
prove
vivo
bind
domain
host
cell
respons
sarscov
entri
cell
antibodi
show
inhibitori
abil
toward
viral
replic
vero
cell
human
form
found
bind
domain
sarscov
protein
k
nm
higher
affin
compar
k
nm
suggest
human
monoclon
antibodi
use
viral
entri
inhibitor
sar
treatment
virtual
screen
aid
identifi
structur
lead
viral
entri
inhibitor
sarscov
compound
emerg
compound
screen
inhibit
pseudoviru
entri
sarscov
plaqu
format
ec
valu
mm
mm
respect
twostep
screen
chines
herbal
medicinebas
novel
small
molecul
bind
avidli
protein
perform
well
two
viru
entri
inhibitor
tetraogalloylbdglucos
luteolin
identifi
show
antisarscov
activ
ec
valu
mm
respect
bind
sarscov
taken
vesicl
insid
cell
special
cellular
enzym
cathepsin
act
acid
environ
insid
vesicl
facilit
fusion
viral
membran
vesicl
membran
viral
protein
nucleic
acid
enter
cell
viral
replic
occur
thu
cathepsin
l
inhibitor
repres
attract
start
point
antivir
therapeut
target
sarscov
entri
sever
compound
identifi
shown
inhibitori
activ
sarscov
howev
inform
regard
mechan
action
correspond
target
known
glycyrrhizin
show
inhibitori
activ
sarscov
replic
ec
mgl
viru
absorpt
vero
cell
glycyrrhizin
acid
deriv
found
inhibit
sarscov
replic
vitro
ec
valu
rang
mm
unfortun
compound
show
high
cytotox
viral
entri
step
suspect
inhibit
deriv
nitric
oxid
shown
inhibitori
effect
viru
infect
organ
donor
snitrosonacetylpenicillamin
shown
inhibit
replic
cycl
sarscov
concentrationdepend
manner
probabl
earli
step
infect
hiv
proteas
inhibitor
nelfinavir
antihelminth
drug
niclosamid
antimalari
agent
chloroquin
show
strong
inhibitori
activ
ec
mm
ec
mm
ic
mm
respect
sarscov
replic
howev
cytoprotect
effect
found
nelfinavir
independ
studi
none
forego
compound
show
inhibitori
activ
sarscov
viral
entri
ribavirin
broadspectrum
inhibitor
rna
dna
virus
use
treatment
sar
patient
inhibit
viral
growth
concentr
attain
human
serum
contrast
interferon
ifn
show
vitro
inhibitori
effect
start
concentr
iuml
interestingli
combin
ribavirin
ifn
b
synergist
inhibit
sarscov
replic
unpreced
rapid
basic
understand
sarscov
life
cycl
achiev
alreadi
number
target
includ
sarscov
sarscov
plpro
appear
promis
antisarscov
chemotherapi
sinc
global
outbreak
sar
end
small
number
case
sar
associ
laboratori
exposur
report
howev
identif
chines
horsesho
bat
anim
reservoir
sarscov
potenti
danger
transfer
viru
human
still
exist
date
effect
therapi
treatment
sar
human
structurebas
design
screen
compound
provid
number
promis
structur
lead
sarscov
potent
low
molecular
weight
inhibitor
less
toxic
need
develop
interest
structurebas
design
screen
sarscov
plpro
increas
sinc
xray
structur
sarscov
plpro
recent
determin
develop
antisarscov
chemotherapi
base
viral
entrystep
mechan
hold
promis
requir
explor
interest
determin
antivir
direct
sarscov
effect
recent
identifi
human
coronavirus
caus
respiratori
infect
pneumonia
children
elderli
thu
like
quest
sarscov
chemotherapi
relev
coronavirusrel
ailment
